England's Pharmacies to Expand Prescription Powers This Autumn with £340 Million Investment
Pharmacies across England are set to gain expanded prescribing authority from the autumn, a move intended to streamline patient care and mitigate demand on GP surgeries and hospitals. This builds upon the existing Pharmacy First scheme, launched in 2024, which currently allows pharmacists to prescribe for conditions such as sore throats, earaches, sinusitis, shingles, impetigo, infected bites, and urinary tract infections.
Funding and Industry Concerns
A new £340 million investment will facilitate the addition of five common ailments to this list, although the specific conditions have not yet been disclosed. The Department of Health and Social Care reports that the Pharmacy First scheme facilitated over 3.3 million consultations between March 2025 and February 2026.
However, industry bodies have voiced significant concerns. The National Pharmacy Association (NPA) contends that the new funding package does not adequately address the increasing financial strain on pharmacies, including rising business rates, employer costs, and medicine prices. Dr Olivier Picard, NPA chairman, highlighted that the deal does little to close a £2.5 billion funding gap identified by the NHS a year prior, deeming the expanded scheme “nowhere near ambitious enough” and warning that many pharmacies may struggle to implement it without further losses.
Similarly, Dr Leyla Hannbeck, chief executive of the Independent Pharmacies Association, representing approximately 5,000 pharmacies in England and Wales, acknowledged the changes as a “step in the right direction” but asserted that the funding offered is insufficient to cover the increased workload. This leaves many pharmacies in a precarious financial position.
Future Capacity and Broader Context
From autumn, newly qualified pharmacists will enter the sector with prescribing qualifications integrated into their training, marking the first cohort to receive such comprehensive instruction. These professionals are expected to play a crucial role in the expansion and enhancement of the Pharmacy First scheme.
Health Minister Stephen Kinnock stated that the government is “making the most of our highly skilled pharmacists,” aiming to boost service access and provide care closer to patients’ homes. He emphasised that independent prescribing will be instrumental in easing pressures on GPs and reducing administrative burdens.
Comparable pharmacy-led schemes are already operational in Scotland, Northern Ireland, and Wales, with Scotland's model having served as an initial blueprint for England's Pharmacy First initiative.
